Skip to main content

Size Matters – Special Considerations in the Pediatric IBD Patient

  • Chapter
  • First Online:
Inflammatory Bowel Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1619 Accesses

Abstract

IBD in the pediatric and adult populations shows important distinctions in epidemiology, presenting signs and symptoms, methods of diagnosis, and therapeutic goals. Since roughly 25% of IBD patients are diagnosed while under the care of pediatricians, it is incumbent on all IBD providers to be familiar with the differences that exist across the age span. These age-dependent contrasts emphasize the conceptualization of IBD as representing a group of phenotypically similar diseases rather than two or three distinct entities. This chapter will highlight those areas within the pediatric population that require specific attention by the healthcare team.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin N Am. 2009;38(4):611–628. doi: 10.1016/j.gtc.2009.07.010. Review. PubMed [citation] PMID: 19913205.

  2. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114–1122. doi: 10.1053/j.gastro.2008.06.081. Epub 2008 Jul 3. PubMed [citation] PMID: 18725221.

  3. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16(6):953–961. doi: 10.1002/ibd.21152. PubMed [citation] PMID: 19834970.

  4. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106–1113. doi: 10.1053/j.gastro.2008.06.079. Epub 2008 Jul 3. PubMed [citation] PMID: 18692056.

  5. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, Faubion W Jr, Park R, Heikenen J, Yaffee M, Rivera-Bennett MT, Wiedkamp M, Stephens M, Noel R, Nugent M, Nebel J, Simpson P, Kappelman MD, Kugathasan S. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis. 2013;19(6):1218–1223. doi: 10.1097/MIB.0b013e318280b13e. PubMed [citation] PMID: 23528339.

  6. Dubinsky M. Have we changed the natural history of pediatric Crohn’s disease with biologics? Dig Dis. 2014;32(4):360–363. doi: 10.1159/000358137. Epub 2014 Jun 23. Review. PubMed [citation] PMID: 24969280.

  7. Mandel MD, Miheller P, Müllner K, Golovics PA, Lakatos PL. Have biologics changed the natural history of Crohn’s disease? Dig Dis. 2014;32(4):351–359. doi: 10.1159/000358135. Epub 2014 Jun 23. Review. PubMed [citation] PMID: 24969279.

  8. Levine A, de Bie CI, Turner D, Cucchiara S, Sladek M, Murphy MS, Escher JC; EUROKIDS Porto IBD Working Group of ESPGHAN. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm Bowel Dis. 2013;19(2):370–377. doi: 10.1002/ibd.23013. PubMed [citation] PMID: 22570259.

  9. Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, Lightdale JR, Trenor CC 3rd. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57(3):343–347. doi: 10.1097/MPG.0b013e31829ce5cd. PubMed [citation] PMID: 23752078.

  10. Sunseri WM, Kugathasan S, Keljo DJ, Greer JB, Ranganathan S, Cross RK, Siegel CA, Regueiro MD. IBD LIVE case series--case 3: very early-onset inflammatory bowel disease: when genetic testing proves beneficial. Inflamm Bowel Dis. 2015;21(12):2958–2968. doi: 10.1097/MIB.0000000000000650. No abstract available. PubMed [citation] PMID: 26583935.

  11. Shim JO, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. J Hum Genet. 2014;59(6):337–341. doi: 10.1038/jhg.2014.32. Epub 2014 May 1. PubMed [citation] PMID: 24785691.

  12. Aloi M, Lionetti P, Barabino A, Guariso G, Costa S, Fontana M, Romano C, Lombardi G, Miele E, Alvisi P, Diaferia P, Baldi M, Romagnoli V, Gasparetto M, Di Paola M, Muraca M, Pellegrino S, Cucchiara S, Martelossi S; SIGENP IBD Group. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(4):597–605. doi: 10.1097/01.MIB.0000442921.77945.09. PubMed [citation] PMID: 24569242.

  13. Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroenterol. 2015;21(43):12296–12310. doi: 10.3748/wjg.v21.i43.12296. Review. PubMed [citation] PMID: 26604638, PMCID: PMC4649114.

  14. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM; COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147(5):990–1007.e3. doi: 10.1053/j.gastro.2014.07.023. Epub 2014. Review. PubMed [citation] PMID: 25058236.

  15. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62(12):1795–1805. doi: 10.1136/gutjnl-2012-303956. Review. PubMed [citation] PMID: 24203055.

  16. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–2045. doi: 10.1056/NEJMoa0907206. Epub 2009 Nov 4. PubMed [citation] PMID: 19890111, PMCID: PMC2787406.

  17. Murugan D, Albert MH, Langemeier J, Bohne J, Puchalka J, Järvinen PM, Hauck F, Klenk AK, Prell C, Schatz S, Diestelhorst J, Sciskala B, Kohistani N, Belohradsky BH, Müller S, Kirchner T, Walter MR, Bufler P, Muise AM, Snapper SB, Koletzko S, Klein C, et al. Very early-onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J Clin Immunol. 2014;34(3):331–9. doi: 10.1007/s10875-014-9992-8. Epub 2014 Feb 12. PubMed [citation] PMID: 24519095.

    Google Scholar 

  18. Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth abnormalities persist in newly diagnosed children with Crohn’s disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48(2):168–174. doi: 10.1097/MPG.0b013e318175ca7f. PubMed [citation] PMID: 19179878.

  19. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014;11(10):601–610. doi: 10.1038/nrgastro.2014.102. Epub 2014 Jun 24. Review. PubMed [citation] PMID: 24957008.

  20. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008 ;14(6):839–849. doi: 10.1002/ibd.20378. PubMed [citation] PMID: 18266237.

  21. Wong SC, Dobie R, Altowati MA, Werther GA, Farquharson C, Ahmed SF. Growth and the growth hormone-insulin like growth factor 1 Axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions. Endocr Rev. 2016;37(1):62–110. doi: 10.1210/er.2015-1026. Epub 2015 Dec 31. PubMed [citation] PMID: 26720129.

  22. Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Determination of bone age in pediatric patients with Crohn’s disease should become part of routine care. Inflamm Bowel Dis. 2013a;19(1):61–65. doi: 10.1002/ibd.22979. PubMed [citation] PMID: 22552908.

  23. Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, Rick J, Mack D, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Boyle B, Oliva-Hemker M, Keljo D, Pfefferkorn M, Faubion W, Kappelman MD, Sudel B, Markowitz J, Hyams JS. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–1756. doi: 10.1016/j.cgh.2015.04.010. Epub 2015 Apr 21. PubMed [citation] PMID: 25911120.

  24. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J, Buderus S, Martín-de-Carpi J, De Ridder L, Fagerberg UL, Hugot JP, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López VM, Paerregaard A, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–1207. doi: 10.1016/j.crohns.2014.04.005. Epub 2014 Jun 6. PubMed [citation] PMID: 24909831.

  25. Gupta K, Noble A, Kachelries KE, Albenberg L, Kelsen JR, Grossman AB, Baldassano RN. A novel enteral nutrition protocol for the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2013b;19(7):1374–1378. doi: 10.1097/MIB.0b013e318281321b. PubMed [citation] PMID: 23567777.

  26. Grover Z, Lewindon P. Two-year outcomes after exclusive enteral nutrition induction are superior to corticosteroids in pediatric Crohn’s disease treated early with thiopurines. Dig Dis Sci. 2015;60(10):3069–3074. doi: 10.1007/s10620-015-3722-9. Epub 2015 Jun 3. PubMed [citation] PMID: 26038093.

  27. Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–391. doi: 10.1053/j.gastro.2013.10.027. Epub 2013 Oct 23. PubMed [citation] PMID: 24162032.

  28. Mcmullin CM, Morton J, Vickramarajah S, Cameron E, Parkes M, Torrente F, Heuschkel R, Carroll N, Davies RJ. A comparison of outcomes for adults and children undergoing resection for inflammatory bowel disease: is there a difference? ISRN Gastroenterol. 2014;2014:410753. doi: 10.1155/2014/410753. PubMed [citation] PMID: 25006470, PMCID: PMC4005026.

  29. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct healthcare costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–1913. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17. PubMed [citation] PMID: 18854185, PMCID: PMC2613430.

  30. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080–3091. doi: 10.1007/s10620-012-2289-y. Epub 2012 Jul 12. PubMed [citation] PMID: 22790905.

  31. Sin AT, Damman JL, Ziring DA, Gleghorn EE, Garcia-Careaga MG, Gugig RR, Hunter AK, Burgis JC, Bass DM, Park KT. Out-of-pocket cost burden in pediatric inflammatory bowel disease: a cross-sectional cohort analysis. Inflamm Bowel Dis. 2015;21(6):1368–1377. doi: 10.1097/MIB.0000000000000374. PubMed [citation] PMID: 25839776, PMCID: PMC4437842.

  32. Shepanski MA, Hurd LB, Culton K, Markowitz JE, Mamula P, Baldassano RN. Health-related quality of life improves in children and adolescents with inflammatory bowel disease after attending a camp sponsored by the Crohn’s and Colitis Foundation of America. Inflamm Bowel Dis. 2005;11(2):164–170. PubMed [citation] PMID: 15677910.

    Google Scholar 

  33. De Boer M, Grootenhuis M, Derkx B, Last B. Health-related quality of life and psychosocial functioning of adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(4):400–406. PubMed [citation] PMID: 15803032.

    Google Scholar 

  34. Väistö T, Aronen ET, Simola P, Ashorn M, Kolho KL. Psychosocial symptoms and competence among adolescents with inflammatory bowel disease and their peers. Inflamm Bowel Dis. 2010;16(1):27–35. doi: 10.1002/ibd.21002. PubMed [citation] PMID: 19575356.

  35. Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1755–1764. doi: 10.1002/ibd.20919. Review. PubMed [citation] PMID: 19472359.

  36. Breglio KJ, Rosh JR. Health maintenance and vaccination strategies in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1740–1744. doi: 10.1097/MIB.0b013e318281f5b5. Review. PubMed [citation] PMID: 23689807.

  37. Veereman-Wauters G, de Ridder L, Veres G, Kolacek S, Fell J, Malmborg P, Koletzko S, Dias JA, Misak Z, Rahier JF, Escher JC; ESPGHAN IBD Porto Group. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto group commentary. J Pediatr Gastroenterol Nutr. 2012;54(6):830–837. doi: 10.1097/MPG.0b013e31824d1438. Review. PubMed [citation] PMID: 22584748.

  38. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A. 2003;100(24):13761–13766. Epub 2003 Nov 10. PubMed [citation] PMID: 14610281, PMCID: PMC283495.

    Google Scholar 

  39. Fuchs Y, Markowitz J, Weinstein T, Kohn N, Choi-Rosen J, Levine J. Pediatric inflammatory bowel disease and imaging-related radiation: are we increasing the likelihood of malignancy? J Pediatr Gastroenterol Nutr. 2011;52(3):280–285. doi: 10.1097/MPG.0b013e3181f57177. PubMed [citation] PMID: 21297507.

  40. Berrington de González A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet. 2004;363(9406):345–351. PubMed [citation] PMID: 15070562.

    Google Scholar 

  41. Sauer CG, Kugathasan S, Martin DR, Applegate KE. Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses. Inflamm Bowel Dis. 2011;17(11):2326–2332. doi: 10.1002/ibd.21626. Epub 2011 Jan 13. PubMed [citation] PMID: 21987300.

  42. Swanson G, Behara R, Braun R, Keshavarzian A. Diagnostic medical radiation in inflammatory bowel disease: how to limit risk and maximize benefit. Inflamm Bowel Dis. 2013;19(11):2501–2508. doi: 10.1097/MIB.0b013e31828dc6b6. Review. PubMed [citation] PMID: 23792551.

  43. Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, Guthery SL, Cucchiara S, Kim CE, Frackelton EC, Annaiah K, Glessner JT, Santa E, Willson T, Eckert AW, Bonkowski E, Shaner JL, Smith RM, Otieno FG, Peterson N, Abrams DJ, Chiavacci RM, Grundmeier R, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40(10):1211–5. doi: 10.1038/ng.203. Epub 2008 Aug 31. PubMed [citation] PMID: 18758464, PMCID: PMC2770437.

  44. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149(5):1163–1176.e2. doi: 10.1053/j.gastro.2015.08.001. Epub 2015 Aug 7. Review. PubMed [citation] PMID: 26255561.

  45. Benor S, Russell GH, Silver M, Israel EJ, Yuan Q, Winter HS. Shortcomings of the inflammatory bowel disease serology 7 panel. Pediatrics. 2010;125(6):1230–1236. doi: 10.1542/peds.2009-1936. Epub 2010 May 3. PubMed [citation] PMID: 20439597.

  46. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–1321. doi: 10.1002/ibd.21493. Epub 2010 Nov 8. PubMed [citation] PMID: 21560194.

  47. Dubinsky M, Braun J. Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases. Gastroenterology. 2015;149(5):1265–1274.e3. doi: 10.1053/j.gastro.2015.08.006. Epub 2015 Aug 15. Review. PubMed [citation] PMID: 26284597.

  48. Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG. Utility of serum antibodies in determining clinical course in pediatric Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(2):139–146. PubMed [citation] PMID: 15017619.

    Google Scholar 

  49. Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18(10): 1872–1884 PMC [article] PMCID: PMC3342398, PMID: 22294465, DOI: 10.1002/ibd.22862.

  50. Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, Yamauchi R, Fukunaga S, Torimura T. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304–1310. doi: 10.3748/wjg.v22.i3.1304. Review. PubMed [citation] PMID: 26811667, PMCID: PMC4716040.

  51. de Silva PS, Fishman LN. Transition of the patient with IBD from pediatric to adult care-an assessment of current evidence. Inflamm Bowel Dis. 2014;20(8):1458–64. doi: 10.1097/MIB.0000000000000045. Review. PubMed [citation] PMID: 24846721

  52. Gray WN, Maddux MH. Current transition practices in pediatric IBD: findings from a National Survey of pediatric providers. Inflamm Bowel Dis. 2016;22(2):372–379. doi: 10.1097/MIB.0000000000000642. PubMed [citation] PMID: 26752464.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joel R. Rosh MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Koslowe, O., Rosh, J.R. (2017). Size Matters – Special Considerations in the Pediatric IBD Patient. In: Cohen, R. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-53763-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53763-4_15

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-53761-0

  • Online ISBN: 978-3-319-53763-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics